Catalyst Pharmaceuticals (CPRX) Accumulated Expenses (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 16 years of Accumulated Expenses data on file, last reported at $136.0 million in Q4 2025.

• Quarterly Accumulated Expenses rose 34848.59% year-over-year to $136.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $136.0 million (up 34848.59% YoY) and the FY2025 annual result came in at $136.0 million, up 34848.59% from the prior year.
• Accumulated Expenses climbed to $136.0 million in Q4 2025, from $119.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $136.0 million in Q4 2025 to a low of $347000.0 in Q2 2025.
• A 5-year average of $41.7 million and a median of $33.2 million in 2021 frame the typical range for Accumulated Expenses.
• The widest YoY moves for Accumulated Expenses: up 34848.59% in 2025, down 99.59% in 2025.
• Tracing CPRX's Accumulated Expenses over 5 years: stood at $24.3 million in 2021, then surged by 120.68% to $53.6 million in 2022, then advanced by 14.28% to $61.3 million in 2023, then tumbled by 99.37% to $389000.0 in 2024, then jumped by 34848.59% to $136.0 million in 2025.
• The last three Accumulated Expenses figures came in at $136.0 million (Q4 2025), $119.6 million (Q3 2025), and $347000.0 (Q2 2025), per Business Quant data.